Overview

Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects

Status:
COMPLETED
Trial end date:
2024-07-06
Target enrollment:
Participant gender:
Summary
To evaluate if the trial drug vamorolone is able to block a specific receptor in the body called mineralocorticoid receptor. This receptor helps to regulate salt and water balance.
Phase:
PHASE1
Details
Lead Sponsor:
Santhera Pharmaceuticals
Treatments:
Drugs, Investigational
Eplerenone
Fludrocortisone
VBP15 compound